Marco Vignetti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients	EJHAEM	2024
Financial toxicity and health-related quality of life in long-term survivors of acute promyelocytic leukaemia	BMJ SUPPORTIVE & PALLIATIVE CARE	2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2024
QUALITY OF LIFE BENEFITS OF ATO VS CHEMOTHERAPY IN PATIENTS WITH APL ARE SUSTAINED OVER TIME: RESULTS FROM THE GIMEMA APL0406	HEMASPHERE	2024
DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. ELIGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI: THE LABNET CML NATIONAL NETWORK	HEMASPHERE	2024
BASELINE QUALITY OF LIFE DATA MAY PREDICT ACHIEVEMENT OF EMR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TKIS: RESULTS FROM THE GIMEMA-SUSTRENIM TRIAL	HEMASPHERE	2024
HEALTH-RELATED QUALITY OF LIFE IN ITALIAN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS COMPARED TO THE GENERAL POPULATION: GIMEMA PROPHECY STUDY	HEMASPHERE	2024
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study	HAEMATOLOGICA	2024
Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia	BLOOD	2024
Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis	JOURNAL OF CLINICAL ONCOLOGY	2023
P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE	HEMASPHERE	2023
P523: The comparison of VFLAI, FLAI and 3 + 7 regimens by multilevel propensity score weighting highlights the benefit of the addition of venetoclax in no low risk aml treated in Gimema trials real world	HEMASPHERE	2023
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA	HEMASPHERE	2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia	CANCER	2023
Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia	BLOOD	2023
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia	THE JOURNAL OF MOLECULAR DIAGNOSTICS	2022
Lymphadenopathies before and during the pandemic COVID-19: increasing incidence of metastases from solid tumors	JOURNAL OF CLINICAL MEDICINE	2022
The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials	BLOOD	2022
Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform	FRONTIERS IN ONCOLOGY	2022
Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden	BMJ SUPPORTIVE & PALLIATIVE CARE	2022